| Name | Crism Therapeutics Corporation Ord Npv |
|---|---|
| Epic | CRTX |
| Isin | VGG042401262 |
| Industry | n/a |
| Latest share price | 9.50p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £3.10 | Debt ratio | n/a |
| Shares in issue | 32.68 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | n/a |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | n/a | 52-week high / low | 9.00p / 18.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Crism Therapeutics Corporation Ord Npv |
|---|---|
| Address | Kingston Chambers, PO Box 173, Road Town, Tortola, British Virgin Islands, USA |
| Telephone | +1 (925) 408 4621 |
| Website | http://www.crismtherapeutics.com/ |
| Director | Position |
|---|---|
| Mr Andrew James Webb | CEO |
| Dr Nermeen Yunus Varawalla | Non-Executive Chairman |
| Mr Gerald Beaney | Independent Non-Executive Director |
| Mr Christopher McConville | Chief Scientific Officer |
| Assets |
|---|
| Liabilities |
|---|
| Net assets |
|---|
| Equity |
|---|
| Income |
|---|